Xtant Medical stock sits 66.32 percent below its 52-week high

Published on 10/07/2026 at 06:34 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Xtant Medical stock had a Lang & Schwarz prior close of EUR 0.29 on October 5, 2026. Q2 revenue was USD 23.03 million, below USD 24.88 million estimates.

XTNT, US98420P3082, Illustration mit AI erstellt.

Xtant Medical stock had a Lang & Schwarz prior close of EUR 0.29 on October 5, 2026. The primary-market quote was USD 0.32 on October 6, leaving the stock 66.32 percent below its USD 0.95 52-week high.

Stock remains below its yearly high

The USD 0.32 quote and USD 0.27 to USD 0.95 52-week range came from the October 6 market snapshot. Xtant Medical's market capitalization was USD 45.0 million on the same date, while volume reached 201,683 shares.

That valuation places the small medical-device company close to its yearly low in absolute terms, but the 0.05-dollar gap to the low is materially smaller than the 0.63-dollar gap to the high. The chart therefore leaves investors weighing recovery potential against the company's latest operating loss.

Revenue misses second-quarter estimates

In the second quarter of 2026, Xtant Medical reported revenue of USD 23.03 million and a consolidated net loss of USD 9.41 million. MarketBeat reported that revenue missed the USD 24.88 million analyst estimate and diluted earnings per share came in at a loss of USD 0.07 versus an expected loss of USD 0.02.

The comparison matters because revenue increased from USD 20.88 million in the first quarter of 2026, yet the second-quarter loss widened from USD 3.09 million. Cash and cash equivalents stood at USD 9.87 million on June 30, 2026, while operating cash flow was negative USD 7.31 million in the quarter.

BioHorizons adds a growth channel

Xtant Medical's most recent named commercial development was an exclusive partnership with BioHorizons to expand access to its allogeneic growth factor technology in the dental market, dated August 27, 2026. Ventureline lists the partnership alongside the second-quarter results and earnings-call materials.

The commercial angle is consistent with the company profile on its investor page, which describes Xtant Medical as a designer, manufacturer and marketer of regenerative biologics and spinal implant systems. The partnership broadens the addressable use of an existing technology, while the second-quarter figures show that execution and cash consumption remain central measures for the next report.

Trading reference for October 6

The last prior close at Lang & Schwarz was EUR 0.29 on October 5, 2026. The October 6 market data showed USD 0.32 on the primary market, with the USD 0.27 to USD 0.95 range and USD 45.0 million market capitalization providing the dated valuation context.

The further course of trading is shown by the continuously updated real-time quote of Xtant Medical stock.